Cognition Therapeutics (CGTX) Return on Equity (2021 - 2026)

Cognition Therapeutics (CGTX) has 6 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• Quarterly Return on Equity rose 2.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (up 2.0% YoY) and the FY2025 annual result came in at 0.02%, changed 0.0% from the prior year.
• Return on Equity advanced to 0.01% in Q1 2026 per CGTX's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Equity topped out at 0.0% in Q1 2022 and bottomed at 0.05% in Q2 2025.
• The 5-year median for Return on Equity is 0.01% (2025), against an average of 0.02%.
• Peak annual rise in Return on Equity reached 2 bps in 2025, while the deepest fall reached 3 bps in 2025.
• Tracing CGTX's Return on Equity over 5 years: stood at 0.01% in 2022, then tumbled by 93 bps to 0.02% in 2023, then sank by 112 bps to 0.03% in 2024, then surged by 58 bps to 0.01% in 2025, then increased by 1 bps to 0.01% in 2026.
• Per Business Quant, the three latest CGTX Return on Equity figures stand at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.02% (Q3 2025).

Peer Comparison